Sramana Mitra: Funding was happening in Israel? Rotem Shor: Seed and Series A was in Israel. In Round B, non-Israeli venture funds joined. Sramana Mitra: By Series B, you had the third client? Rotem Shor: Yes, but we had more of a thesis. We still got traction from users. Sramana Mitra: How much money are
Sramana Mitra: How did the first one get the users? Rotem Shor: They paid a very small amount of money. It was not only for a specific medication. They developed it as a tool. The second was very specific for their drug. We found out later that it is much harder than we thought. Sramana
Sramana Mitra: You went to a pharma company before you had a product? Rotem Shor: We developed a concept. Then we developed the MVP. We launched it to users. We launched the product and saw that users were coming. We did a lot of guerilla marketing. We combined it all together. We gained traction. We
Rotem represents yet another point of view of a software developer/technologist who successfully transitioned to an entrepreneur in an unfamiliar domain: pharmaceutical. In that journey, he paired up with his brother who was more the business person in the duo. This is a common strategy for developers to become entrepreneurs, although, I generallybelieve that developers